In addition, we have shown that the RGC reprogramming efficiency from MG by TFs is similar in both young and aged Brn3b null mutant mice, making it feasible to treat not only young but also aged patients with glaucoma and other optic neuropathies by this regeneration strategy. This evidence concerns the gene POU4F2 and optic nerve disorder.